The described results highlight that the differential expression of GPR21 and GPR82 receptors in various tissues is not only associated with the MetS but also depends on the etiology of the syndrome, thus being selective candidates for new therapeutic targets of metabolic diseases depending on their cause. This evidence concerns the gene GPR21 and metabolic syndrome.